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HIGHLIGHTS 
 Patients diagnosed were aged 30-49 years 
 Highest comorbidity are hypertension, diabetes mellitus and cardiac disease 
 Large-scale Social Restrictions or “Pembatasan Sosial Berskala Besar (PSBB)” policy  
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COVID-19 has experienced an increase in 2,995,758 positive 
cases and 204,987 deaths, in distribution areas of more than 
213 countries. This research using a systematic literature 
review, policy brief and internet-based questionnaire with the 
aim of finding out the diagnosis and epidemiology of 
Coronavirus (COVID-19) outbreak in Indonesia. The cases in 
Indonesia have reached 9,771 and killed 784 people, possibly 
as many as of 19 cases are asymptomatic but can be carriers 
of the virus. The diagnosis is carried out by rapid testing and 
using a polymerase chain reaction (PCR). Most of the patients 
diagnosed were aged 30-49 years (38.91%), the highest 
accompanying diseases were hypertension (34.85%), diabetes 
mellitus (25.76%) and cardiac disease (17.05%). The most 
signs and symptoms are that the patient has a cough, 
shortness of breath and has a history of internal medicine and 
fever. Based on sex mostly experienced by men (58.94%) 
compared to women (41.06%). The Government of Indonesia 
is making efforts to reduce the COVID-19 outbreak by 
implementing a health protocol and a Large-scale Social 
Restrictions or “Pembatasan Sosial Berskala Besar (PSBB)” 
policy. 
This is an open-access article under the CC–BY-SA license.   
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1. INTRODUCTION 
Coronavirus outbreak occurred in the world Since mid-December 2019. This disease 
was first discovered in Wuhan City, Hubei, China, which is found in Wuhan's Huanan Seafood 
Wholesale Market or a market of fish and live animals that sell various species of animals.1 It 
has been reported that this disease is caused by SARS-CoV-2 (formerly 2019-nCoV or HCoV-
19). In general, the incubation period is 1 to 14 days (average: 5-6 days) but can reach 92 for 
24 days.2 The most commonly seen characteristics of COVID-19 are fever, cough and 
abnormal chest computed tomography (CT).3 On Feb 11, 2020, The World Health 
Organization (WHO) declared a 2019 coronavirus disease (Covid-19) as a pandemic. To date 
Apr 29, 2020, COVID-19 has experienced an increase in cases of 2,995,758 positive and 
204,987 died. Spread areas occur in more than 213 countries including Indonesia, this is a 
global threat.4 The prevalence of the COVID-19 pandemic in Indonesia, based on a report on 
Apr 29, 2020, showed an increase in cases, of which 9,771 were positive, 1,391 recovered 
and 784 died.5 
This disease appears inseparable from the role of animals or zoonoses in transmission 
to humans, bats, anteater and dogs that are suspected to be their hosts.6,7 Human to human 
transmission from Covid-19 occurs mainly through respiratory droplets, direct contact, 
asymptomatic transmission, and intrafamilial transmission.2,8 
COVID-19 can affect any demographics, including old age, children, and pregnant 
women. Therefore to stop transmission of the virus and save the lives of its citizens, the 
Indonesian government implements strategies and tactics including protocol directives from 
the World Health Organization (WHO) such as free testing with rapid tests and PCR, free 
treatment, the establishment of COVID-19 hospitals, large-scale social restrictions, and 
volunteering and involving social organizations to handle this pandemic. 
To see an overview of the outbreak and management of COVID-19 handling in 
Indonesia, there needs to be an epidemiological study based on data reports from various 
sources, especially the Task Force for the Acceleration of Handling COVID-19 from the 
Ministry of Health of the Republic of Indonesia and a review of articles from various available 
sources and references. It is hoped that this study will be able to explain the understanding of 
COVID-19, which causes high mortality rates and suggest developing strategies to overcome 
future epidemic threats. 
 
2. REVIEW METHOD 
A narrative review was conducted using Elsevier, Medline / PubMed, Scopus, and Web 
of Science. The search terms use keywords: "Novel coronavirus," "Novel coronavirus 2019", 
"2019 nCoV", "Covid-19", "diagnosis". Observation studies and case reports for calculating 
prevalence were obtained from the policy brief and the report of the Task Force for the 
Acceleration of COVID-19 Handling of the Ministry of Health of the Republic of Indonesia. We 
also presented a survey policy brief to assess compliance with the physical, social distancing 
of the Research and Development Center for Humanities and Health Management, Litbang 
RI online (internet, Facebook, Instagram, Twitter, WhatsApp) 19.654 respondents spread in 
34 provinces in Indonesia. 
 
3. RESULTS AND DISCUSSION 
Pathogenesis  
Coronavirus 2019 is an inflammatory lung parenchymal disease caused by severe 
acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clinical symptoms that arise vary 
from shock without complications (mild) to septic (severe).9,10  Coronavirus is the only positive 
RNA virus, which is encapsulated, not segmented. There are four genera, namely alpha 
coronavirus, betacoronavirus, deltacoronavirus and gamma coronavirus. Severe respiratory 
failure in COVID-19 is commonly associated with the hyperinflammatory syndrome. Cytokine 
storms may cause hyper inflammation in severe SARSCoV-2 disease.11 
Coronaviruses have capsules, round or elliptical particles, often pleomorphic with 
diameters of around 50-200 nm and coronavirus structures form cube-like structures with 
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protein S located on the surface of the virus.12,13 The envelope is studded with projecting 
glycoproteins and surrounds a core consisting of matrix protein enclosed within which is a 
single strand of positive-sense RNA (Mr 6 × 106) associated with nucleoprotein. The envelope 
glycoproteins are responsible for attachment to the host cell and also carry the main antigenic 
epitopes, particularly the epitopes recognized by neutralizing antibodies. OC43 also 
possesses a haemagglutinin. 
Coronavirus is sensitive to heat and can effectively be activated by disinfectants 
containing chlorine, lipid solvents with a temperature of 56 ℃ for 30 minutes, ether, alcohol, 
peroxyacetic acid, non-ionic detergents, formalin, oxidizing agents and chloroform. 
Chlorhexidine is not effective in deactivating the virus. Coronavirus infections usually occur 
frequently in winter and humidity is not too high.12,13 
This new type of Coronavirus pneumonia can occur in all people, especially 
immunocompromise. If exposed to large amounts of the virus at one time, can cause disease 
even though the body's immune system is functioning normally. People with weak immune 
systems such as the elderly, pregnant women, and other conditions, can cause the disease 
progressively faster and more severely. Coronavirus infection causes a weakened immune 
system against this virus so re-infection can occur.12,13 
The main clinical symptoms of COVID-19 infection are fever (temperature> 38ºC), 
cough and difficulty breathing. Moreover, it can be accompanied by heavy tightness, fatigue, 
myalgia, gastrointestinal symptoms such as diarrhoea and other respiratory symptoms. In 
some patients, mild symptoms are not accompanied by fever.12,13 Besides, fever and cough 
are reported to be the most common symptoms associated with COVID-19 patients.3 
However, mild symptoms such as nausea, headaches, respiratory problems, sore throat, 
myalgia, vomiting and sometimes diarrhoea were also shown in COVID-19 patients.3,14 
A meta-analysis study from journals concluded that COVID 19 patients would be 
exacerbated by comorbidities including was fever (91 ± 3, 95% CI 86-97%), followed by cough 
(67 ± 7, 95% CI 59-76%), fatigue (51 ± 0, 95% CI 34-68%) and dyspnea (30 ± 4, 95% CI 21-
40%). The most prevalent comorbidities were hypertension (17 ± 7, 95% CI 14-22%) and 
diabetes (8 ± 6, 95% CI 6-11%), followed by cardiovascular diseases (5 ± 4, 95% CI 4-7 %) 
and respiratory system disease (2 ± 0, 95% CI 1-3%). Compared with the Non-severe patient, 
the pooled odds ratio of hypertension, respiratory system disease, cardiovascular disease in 
severe patients were (OR 2.36, 95% CI: 1.46-3.83), (OR 2.46, 95% CI: 1.76-3.44) and (OR 
3.42, 95% CI: 1.88-6.22) respectively.15 
The spread of the virus can be through close contact, environment or objects 
contaminated with the virus, airway droplets, and airborne particles. A droplet is particle-
containing water with a diameter of> 5um. Droplets can pass up to a certain distance (usually 
1 meter) to the vulnerable mucosal surface. Droplet particles are large enough so that they 
will not last or settle in the air for a long time. Droplet production from the airways includes 
coughing, sneezing or talking as well as invasive respiratory procedures such as sputum 
aspiration or bronchoscopy, tracheal tube insertion. Airborne particles are particles with a 
diameter of less than 5um, which can spread over long distances and are still infectious. 
Airborne pathogens can spread by contact. Direct contact is the transmission of pathogens 
directly with the skin or mucous membranes, blood or blood fluid that enters the body through 
mucous membranes or damaged skin.12,13 
 
Diagnosis 
Laboratory markers of disease progression and clinical outcomes,  such as  D-dimer,  
C-Reactive Protein (CRP), procalcitonin, neutrophil count, lymphocyte count and inflammatory 
cytokines were monitored.2,11 Regarding laboratory findings, decreased albumin (75.8%, 
95%CI 30.5–100.0%), high C-reactive protein (58.3%, 95%CI 21.8–94.7%), and high lactate 
dehydrogenase (LDH) (57.0%, 95%CI 38.0–76.0), lymphopenia (43.1%, 95%CI 18.9–67.3), 
and high erythrocyte sedimentation rate (ESR) (41.8%, 95%CI 0.0–92.8), were the most 
prevalent laboratory results (Morales, 2020). Diagnostic  tests  for  COVID-19  have  been  
developed  such  as  reverse transcription-polymerase  chain  (RT-PCR),  real-time  PCR,  
real-time  quantitative  RT-PCR  (rRTqPCR),  COVID-19-RdRp/Hel  real-time  RT-PCR assay, 
 DIAGNOSIS AND EPIDEMIOLOGY       Sutaryono 
 
52 
POCT/bedside testing, loop-mediated isothermal amplification (RT-LAMP), full genome 
analysis by next-generation sequencing (NGS), fluorescence-based  quantitative  PCR  assay, 
enzyme-linked  immunosorbent  assay  (ELISA), computed tomography technique (CT) 
imaging and X-Ray.9,16,17 
Histologically, tissue biopsy of the lungs, liver and heart tissue reveals pneumococcal 
desquamation, hyaline membrane formation, diffuse bilateral alveolar damage in conjunction 
with cellular fibromyxoid exudates. Multiple nucleated syncytial cells, atypical enlarged 
pneumocytes, interstitial mononuclear inflammatory infiltrates along with the presence of the 
majority of lymphocytes in the affected lung configuring significant cytopathic effects.11 Nearly 
all COVID-19 patients are reported to have varying degrees of disability in lung pneumonia 
with other viruses on CT imaging. In addition, other findings include bilateral multilobular sub-
lateral consolidation of the lungs at an early stage followed by multiple mottling and ground-
glass opacity.9,11 
Severe pulmonary lesions are seen around the 10th day after initial symptoms in most 
patients recovering from COVID-19 disease.18 The blood profile of COVID-19 patients showed 
lymphopenia, leukopenia, thrombocytopenia and anaemia, along with higher aspartate 
aminotransferase levels and hypersensitive troponin.9,11 Initially reported to be normal, but a 
slight increase in level in the later stages was noted, indicating the possibility of secondary 
infection.11 Cytokine storm associated with the rampant inflammation resulted into the release 
of proinflammatory cytokines and chemokines like  IFN-, IL-1, IP-10, MCP-1, TNF-α, G-
CSF, MCP-1, IP-10,  and MIP-1A which severely damages pulmonary tissues leading to death 
in severe COVID-19 patients. Although, lymphopenia, leucopenia,  thrombocytopenia, and 
RNAaemia occurs with a decrease in helper T cells, regulatory T  cells, and memory T cells 
in severe COVID-19 cases notably the levels of Th1 and Th2 cytokines are found elevated. 
However, elevated levels of ALT, AST, LDH, CPK, creatinine, γ-GT and α-HBDH in  a  severe 
form of the disease suggests multiorgan  involvement.16 
 
COVID-19 Epidemiology in Indonesia 
On April 28, 2020, Data from World Health Organization (WHO), there were 2,954,222 
positive COVID-19 cases and 202,597 dead, spreading over 213 countries. Cases in several 
countries show European Region 1,386,693 confirmed (27,313) 126,429 deaths (1,904), 
Region of the Americas 1,179,607 confirmed (39,087) 60,211 deaths (1,722), Eastern 
Mediterranean Region, 171,238 confirmed (5,305), 7,148 deaths (157), Western Pacific 
Region 145,385 confirmed (1,264) 5,998 deaths (40), South-East Asia Region 48,348 
confirmed (2,288) 1,917 deaths (93) African Region, 22,239 confirmed (769) 881 deaths.19 
The official statistics of the epidemic in Indonesia were reported by the Ministry of 
Health through the Task Force for the Acceleration of Handling COVID-19, 2020, on Apr 29, 
2020, the cumulative number of positive cases was 9,771 recovered 1,391 and 784 people 
died (cluster/web). Figure 1 shows the distribution of confirmed cases5 in April 2020.  
 
 
Figure.1 Distribution of Confirmed Cases during April 2020 in Indonesia5 
 
 At the beginning of April, there were 114 confirmed cases, further increasing until 
the second week, there were 407 cases. Fluctuations occurred from the third week to the 
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fourth week and even dropped by only 214 cases, but the next day there was an increase 
again. Starting at the end of the month, the fluctuation case has begun to stabilize or decrease, 
and this is due to the Indonesian government making policies with large-scale social 
restrictions. The number of COVID-19 cases above is substantially possible still below 
proportion because the data are only based on rapid tests or by polymerase chain reaction 
(PCR) while many people have not been confirmed even though they have the potential to be 
carriers of asymptomatic viruses. It has been speculated that the total number of COVID-19 
infected people is about five times higher than the official statistics. This bias must be taken 
into account when interpreting any COVID-19 statistics.20 
 The distribution of the COVID-19 case area almost occurred in all provinces in 
Indonesia, the highest being in DKI Jakarta, West Java, East Java, Central Java, followed by 
other provinces. The age of COVID-19 patients in Indonesia who had been diagnosed was 
mostly 30-49 years (38.91%), seen in figure 2. 
 
 
 
Figure 2. Distribution of COVID-19 Cases By Age5 
Figure 2 shows that many cases of COVID-19 death are experienced in older people; this is 
associated with a weak immune system that allows faster development of viral infections and 
comorbidities.21,22 The results of previous studies, most patients heal themselves, while the 
mortality rate is around 10-14%, especially patients over the age of 40 years with comorbidities 
such as heart disease, asthma, chronic lung disease and diabetes.21 The highest incidence of 
COVID-19 with comorbidities in Indonesia was hypertension (34.85%), diabetes mellitus 
(25.76%) and cardiac disease (17.05%). 
 
 
Figure 3.  Signs and Symptoms of COVID-19 patients5 
Based on the signs and symptoms of COVID-19 in figure 3, many patients experience 
coughing, shortness of breath and a history of internal medicine and fever. Research that has 
been done shows signs and symptoms of fever (96%) and cough (51.47%) were the most 
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common symptoms.23 Coronavirus infection in Indonesia by sex is mostly experienced by men 
(58.94%) while women (41.06%).10 
Physical and Social Distancing Compliance 
The results of an online survey with Google form via the internet, Facebook, and 
WhatsApp related to community compliance with physical and social distancing calls, based 
on the results of the RI Ministry of Health Research and Development briefing policy of 19,654 
samples, 99.96% knew about the government's recommendations for physical distancing. 
However, only 54.29% were obeyed keep distance and 8.82% stay at home, 32.09% stated 
that leaving the house to shop for basic needs, 43.99% stated leaving the house for urgent 
needs. from 19,654 respondents who carried out the health protocol, 93.40% used masks, 
17.20% wore gloves, 47.37% said they always brought a hand sanitizer, and 31.79% said they 
gave greetings without contact.24 
Activities that are still a concern in the results of the compliance survey are outdoor 
activities. This cannot be denied because the community needs to fulfil their daily needs, 
besides the policy taken by the government by implementing Large Scale Social Restrictions 
(PSBB) which it is still considered loose not applying total lockdown so that people are free to 
leave the house. 
 
Prevention and Control of COVID-19 Spread 
Public health and control measures are needed to reduce the transmission of COVID-
19 people to people by limiting the global spread of the virus.22  Experience from the early 
phase of SARS-CoV-2 Pneumonia strongly highlighted that travel history, rather than chest 
radiography, is of paramount importance for early detection and isolation of SARS-CoV-2 
pneumonia cases.24 Public services and facilities must provide antiseptic reagents for regular 
hand washing WHO recommends that it is crucial to limit transmission of infection by Physical 
distancing to avoid close contact, especially with health care workers and to prevent 
international outbreaks of avoiding countries or regions of the red zone. In addition, people 
with symptoms of respiratory tract infections should practice cough etiquette, which is to keep 
a distance, cover the cough and sneeze with disposable tissues or clothing, and wash hands, 
and in health care facilities improve infection prevention standards and control practices. 
especially in the emergency department.4 
The Ministry of Health of the Republic of Indonesia issued Regulation No. 9 of 2020 
concerning Large-Scale Social Restriction Guidelines. Some activities are limited as long as 
the regions carry out the Large-Scale Social Restrictionincluding restrictions on schools, work 
at the office, religious activities, public facilities, social culture, public transportation and 
defence and security. Efforts that are no less important are guarding public panic, social media 
one-sidedly increases knowledge and understanding, but also has the potential to spread false 
information or false news. Therefore the government needs to provide accurate knowledge 
and prevent hoax information. It is also necessary to make efforts by all components of the 
community by exploring the potential of the community to be empowered and able to play a 
role in preventing the transmission of Covid-19. 
 
4. CONCLUSION 
 The COVID-19 outbreak has become a health threat worldwide, Indonesia is one of 
the countries affected by more than 9,000 cases, and more than 784 people have died. 
Epidemiologically the COVID-19 case in Indonesia occurred in the 34 highest provinces in 
Jakarta, most patients were aged 30-49 years, male sex and many were accompanied by 
comorbid hypertension, DM and heart disease. Efforts to reduce Covid-19 cases by 
implementing health, social and physical distancing protocols through the Large Scale Social 
Restrictions policy. 
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